Tech Company Financing Transactions
Mediar Therapeutics Funding Round
Mediar Therapeutics, operating out of North Cambridge, received $76 million from Amplitude Ventures, ICG Ventures and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
1/7/2026
Transaction Type
Venture Equity
Amount
$76,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to further advance its wholly owned assets, including MTX-474, an antagonist of EphrinB2, being studied in a Phase 2a study in patients with systemic sclerosis (SSc), and MTX-439, a SMOC2 antagonist, proceeding to Phase 1 studies for the treatment of chronic kidney disease (CKD) associated fibrosis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St.
North Cambridge, MA 02139
USA
North Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Mediar is a discovery stage biotechnology company developing treatments to halt, or even reverse, fibrosis. Our platform and pipeline are based on an emerging class of novel targets -- fibrotic mediators -- that play key roles in modulating myofibroblasts.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Meredith Fisher
Chief Scientific Officer
Paul Yaworsky
Browse more venture capital transactions:
Prev: 1/7/2026: mBaaS venture capital transaction
Next: 1/7/2026: Interos venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs